.
HJLI financial statements
* Numbers in thousands
Year |
2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|
Capitalization * |
16 852 | 9 614 | 7 993 | 8 912 |
EV * |
14 112 | 8 595 | 8 611 | 8 611 |
Stock price $ |
45 | 15.25 | 9.31 | 10.38 |
Number of shares * |
374 | 630 | 859 | 859 |
EPS |
-34,83 | -12,10 | -0,01 | -0,01 |
Revenue * |
187 | 31 | 4 | 4 |
Net income * |
-13 043 | -7 625 | -9 | -9 |
Operating profit * |
-7 535 | -7 086 | -9 | -9 |
Total liabilities * |
1 523 | 2 444 | 3 | 3 |
Net debt * |
-2 741 | -451 | -9 | -9 |
Total assets * |
3 559 | 3 434 | 10 | 10 |
Equity * |
2 036 | 990 | 7 098 | 7 098 |
Cash and investments * |
2 741 | 1 307 | 9 | 9 |
Over the past 10 years, the maximum capitalization of Hancock Jaffe Laboratories, Inc. is 16 852, the minimum is 7 993. Maximum net income 0, Minimum net income -13 043. The maximum price of HJLI shares is 45, the minimum price is 9.31.
.
HJLI valuation
Year |
2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|
P/E |
-1,29 | -1,26 | -874,97 | -975,53 |
P/B |
8,28 | 9,71 | 1,13 | 1,26 |
P/S |
90,34 | 307,71 | 1 879,78 | 2 095,82 |
E/P |
-77% | -79% | 0% | 0% |
P/FCF |
-2,65 | -1,54 | -1,02 | -1,13 |
.
HJLI profitability
Year |
2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|
ROE |
-640% | -770% | 0% | |
ROA |
-451% | -222% | -92% | |
ROIC |
-370% | -455% | -135% |